Navigation Links
Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
Date:5/19/2008

f any mitochondrial or other cellular toxicities that may be associated with some nucleoside analogs. The half-life of the triphosphate in primary human hepatocytes is approximately 38 hours, which suggests the possibility for once-daily dosing. Early animal studies indicate that PSI-7851 can achieve concentrations of active triphosphate in the liver of up to 1,000 times higher than PSI-6130 at equivalent doses.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking sta
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
11. Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... The Coalition of State Rheumatology Organizations ... professional rheumatology societies, today released the findings of ... of biosimilars and the potential impact of these ... are medicines that are highly similar, but not ... from generic medications in that it is impossible ...
(Date:7/1/2015)... July 1, 2015 ContraVir Pharmaceuticals, Inc. (NASDAQ: ... development and commercialization of targeted antiviral therapies, announced today ... Healthcare Conference taking place in New York, ... Parker Meridien Hotel. James Sapirstein ... the Company,s business during his live presentation and will ...
(Date:7/1/2015)... INDIANAPOLIS , July 1, 2015 Eli Lilly ... results for the second quarter of 2015 on Thursday, July ... that day with the investment community and media to further ... will begin at 9 a.m. EDT. Investors, media and the ... call through a link that will be posted on Lilly,s ...
Breaking Medicine Technology:Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference 2Lilly Confirms Date and Conference Call for Second-Quarter 2015 Financial Results Announcement 2
... YINCHUAN, China , July ... Nie Wentao,s nutrition intervention technology for type 1,diabetes mellitus. ... technology for diabetes treatment, so it aroused widespread,concern in ... the study of nutrition,interventions on diabetes mellitus for a ...
... July 14 Osseon Therapeutics, Inc., a biomedical ... received a notice of allowance for its spinal vertebral compression ... has thirteen additional patent applications pending in the United ... and devices. The lead inventor for this inaugural patent is ...
Cached Medicine Technology:Dr. Nie Wentao's New Method of Diabetic Nutrition Interventions 2Dr. Nie Wentao's New Method of Diabetic Nutrition Interventions 3Dr. Nie Wentao's New Method of Diabetic Nutrition Interventions 4Dr. Nie Wentao's New Method of Diabetic Nutrition Interventions 5Osseon Receives Patent Allowance for Novel Spinal VCF Treatment Devices 2
(Date:7/2/2015)... ... July 02, 2015 , ... Cs &A, the leader ... announced the release and publication of their newest offering to complement the existing ... Newsletter. , Designed in support of coverage for the full spectrum of ...
(Date:7/2/2015)... ... July 02, 2015 , ... Maddock Douglas is ... and business models. To help manage the increasing demand for innovation as a ... as SVP of Strategic Engagements. , Benkendorf is a seasoned management executive with ...
(Date:7/1/2015)... ... 01, 2015 , ... In the United States, summer has always been the ... Saudi Arabia and Dubai, the summer temperatures are so hot, that July vacationers often ... Sam Saleh of ORA Dentistry Spa notes that a trip to the United States, ...
(Date:7/1/2015)... ... 01, 2015 , ... Dr. Jian-Dong Li, a professor and ... Georgia Research Alliance Eminent Scholar in Inflammation and Immunity, has received a five-year, ... The grant from the National Institute on Deafness and Other Communication Disorders of ...
(Date:7/1/2015)... ... July 01, 2015 , ... The federal court ... http://www.injurybeacon.com/levaquin/lawsuit/ ) has granted the Defendants’ Motion for Summary Judgment. According to an ... June 26th, the Court rejected the Plaintiff’s assertion that one manufacturer can ...
Breaking Medicine News(10 mins):Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 2Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 3Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 4Health News:Business Builder Mark Benkendorf Joins Innovation Firm Maddock Douglas 2Health News:Dr. Sam Saleh Invites Vacationing International Patients to Get a Same-Day Hollywood Smile During the July Travel Season 2Health News:Institute for Biomedical Sciences Researcher Gets $1.6 Million to Develop Anti-Inflammatory Drug 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 3
... By Jenifer Goodwin HealthDay Reporter , THURSDAY, ... Ellie, was diagnosed with a severe peanut allergy, the New ... and never leaves home without it. The device contains ... even life-threatening allergic reactions. But it,s not only Able ...
... , THURSDAY, Feb. 9 (HealthDay News) -- The number ... to engage in regular exercise has increased steadily over ... health officials. The U.S. Centers for Disease Control ... more Americans lower their risk for chronic illnesses, reduce ...
... Feb. 9, 2012 Wake Forest Baptist Medical Center ... into tumors and heating them with a quick, 30-second laser ... effort involving kidney tumors was published in 2009, but now ... tumors, specifically the tumor initiating cancer stem cells. These stem ...
... and under-studied subset of diseases affecting the lymphatic system ... disease is the focus of a special issue of ... published by Mary Ann Liebert, Inc. . The ... Guest Editor, and Journal Associate Editor Francine ...
... certain cancer cells may exhibit greater flexibility than normal ... tumor growth. Now computer simulations developed by Boston University ... the University of Texas at Austin appear to support ... cells that they,ve created indicates that the softening of ...
... 9 (HealthDay News) -- ,The longer Hispanic women live in the ... birth, a new study says. Researchers analyzed data from 2,141 ... the U.S. National Health and Nutrition Examination Survey 1999-2006. The ... for women who had lived in the United States for less ...
Cached Medicine News:Health News:More People Need Training in Lifesaving Epinephrine Use, Advocates Say 2Health News:More People Need Training in Lifesaving Epinephrine Use, Advocates Say 3Health News:More U.S. Doctors Are Urging Patients to Exercise: CDC 2Health News:Nanotube therapy takes aim at breast cancer stem cells 2Health News:Boston University research suggests new pathways for cancer progression 2
HST, multi frequency Side Fire "T intraoperative transducer. A wide field of view is this transducers benefit....
Super High Density, 120 field of view, angled handle, multi-frequency, convex endovaginal transducer....
Provides tremendous image quality along with a 180 degree field of view....
Prostate biopsy transducer....
Medicine Products: